Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Gynecologic 1Breast 1

Conditions

Mesothelioma, Malignant 1FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma 1Endometrial Neoplasms 1Breast Neoplasms 1

Interventions

Pemetrexed 7Cisplatin 7Cyclophosphamide 5pembrolizumab 4fludarabine 4Platinum 3Drug Therapy 3aldesleukin 2Nivolumab 2Ipilimumab 2Interleukin-2 21,2-diaminocyclohexaneplatinum II citrate 2vatalanib 1spartalizumab 1regorafenib 1napabucasin 1methoxyamine 1fludarabine phosphate 1enzalutamide 1cediranib 1avelumab 1atezolizumab 1anetumab ravtansine 1Vorinostat 1Thiostrepton 1Tetrahydrouridine 1Radiosurgery 1Megestrol Acetate 1Levoleucovorin 1Leucovorin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Mesothelioma, Malignant × Megestrol Acetate × Clear all
NCT00002465 2013-11-06

High-Dose Megestrol in Treating Patients With Metastatic Breast Cancer, Endometrial Cancer, or Mesothelioma

National Cancer Institute (NCI)

Phase 1/2 Unknown
BreastGynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Breast Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡